Aprepitant Regimen의 고용량 Cisplatin 유발 오심 및 구토 예방 효과
The Effect of Aprepitant Regimen on the Prevention of High-Dose Cisplatin-Induced Nausea and Vomiting
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Aprepitant is a substance P/neurokinin-1 (NK1)-receptor antagonist that was approved in 2003 for prevention of CINV. In addition, updated anti-emetic guidelines that include the aprepitant regimen have been published by NCCN and ASCO. However there is scarce clinical data in Korea. The prospective study was performed to evaluate the prevention of high dose cisplatin induced nausea and vomiting in all patients who started high-dose cisplatin-based chemotherapy at our hospital. We checked the nausea severity and vomiting episodes by calling patients within 4 to 5 days after chemotherapy. The retrospective study was performed to compare the prevention of CINV in solid tumor patients who switched their anti-emesis regimen from the standard regimen to the aprepitant regimen. In aprepitant regimen, aprepitant was added to the same anti-emetic regimen used during previous cycles. We checked the nausea, vomiting grades and adverse events in electronic medical records (EMR). In prospective study, 195 patients were included in the analysis. 88.2% of patients achieved a complete response (no emesis and no rescue therapy). In retrospective study, 54patients were reviewed. With aprepitant regimen, nausea and vomiting grades were improved in 22 patients (40.7%)and in 9 patients (16.7%), respectively. Compared with standard regimen, addition of aprepitant provided superior prevention against CINV in Korean patients receiving highly emetogenic cisplatin-based chemotherapy. Moreover, aprepitant significantly prevented CINV in patients who received the standard regimen to prevent CINV in previous chemotherapy cycles.
Abstract
Aprepitant is a substance P/neurokinin-1 (NK1)-receptor antagonist that was approved in 2003 for prevention of CINV. In addition, updated anti-emetic guidelines that include the aprepitant regimen have been published by NCCN and ASCO. However there is scarce clinical data in Korea. The prospective study was performed to evaluate the prevention of high dose cisplatin induced nausea and vomiting in all patients who started high-dose cisplatin-based chemotherapy at our hospital. We checked the nausea severity and vomiting episodes by calling patients within 4 to 5 days after chemotherapy. The retrospective study was performed to compare the prevention of CINV in solid tumor patients who switched their anti-emesis regimen from the standard regimen to the aprepitant regimen. In aprepitant regimen, aprepitant was added to the same anti-emetic regimen used during previous cycles. We checked the nausea, vomiting grades and adverse events in electronic medical records (EMR). In prospective study, 195 patients were included in the analysis. 88.2% of patients achieved a complete response (no emesis and no rescue therapy). In retrospective study, 54patients were reviewed. With aprepitant regimen, nausea and vomiting grades were improved in 22 patients (40.7%)and in 9 patients (16.7%), respectively. Compared with standard regimen, addition of aprepitant provided superior prevention against CINV in Korean patients receiving highly emetogenic cisplatin-based chemotherapy. Moreover, aprepitant significantly prevented CINV in patients who received the standard regimen to prevent CINV in previous chemotherapy cycles.
참고문헌 (23)
- Naeim A, "Evidence-based recommendations for cancer nausea and vomiting", J Clin Oncol, 26(23), pp.3901~3910 (2008)
- 김용범, "Cisplatin을 포함한 항암화학요법 치료 시 환자에서 발생하는 오심 및 구토에서의 정맥주사용 및 경구용 Tropisetron과 Ondansetron의 비교연구", 대한산부회지, 41(10), pp.2544~2550 (1998)
- Poli BS, "Aprepitant protocol 054 study group. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting", cancer, 97(12), pp.3090~3098 (2003)
- Hesketh PJ, "Chemotherapy-induced nausea and vomiting", N Engl J Med, 358, pp.2482~2494 (2008)
- Lohr L, "Chemotherapy-induced nausea and vomiting", The Cancer Journal, 14(2), pp.85~93 (2008)
- Hesketh PJ, "Proposal for classifying the acute emetogenicity of cancer chemotherapy", J Clin Oncol, 15, pp.103~109 (1997)
- F. Roila, "Prevention of chemotherapy-and radiotherapyinduced emesis: Results of the Perugia consensus conference antiemetic subcommittee of the multinational association of supportive care in cancer (MASCC)", Annals of Oncology, 9, pp.811~819 (1998)
- Hesketh PJ, "New treatment options for chemotherapyinduced nausea and vomiting", Support Care Cancer, 12, pp.550~554 (2004)
- Hesketh PJ, "The Oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: A multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin-the aprepitant protocol 052 study group", J Clin Oncol, 21, pp.4112~4119 (2003)
- Andrews PL, "Abdominal vagal afferent neurones: an important target for the treatment of gastrointestinal dysfunction", Curr Opin Pharmacol, 2, pp.650~656 (2002)
- Navari RM, "a neurokinin-1 receptor antagonist with anti-emetic and anti-nausea activities", Curr Opin Investig Drugs, 9(7), pp.774~785 (2008)
- Van Belle SJ, "Fosaprepitant dimeglumine (MK-0517 or L-785,298), an intravenous neurokinin-1 antagonist for the prevention of chemotherapy induced nausea and vomiting", Expert Opin Pharmacother, 9(18), pp.3261~3270 (2008)
- "National comprehensive cancer network clinical practice guideline in oncology", Antiemesis V.3, ~ (2008)
- Kris MG, "American society of clinical oncology guideline for antiemetics in oncology", J Clin Oncol, 24(18), pp.2932~2947 (2006)
- Gralla RJ, "Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines", J Clin Oncol, 16, pp.1174~1178 (1999)
- Majumdar AK, "Pharmacokinetics of aprepitant after single and multiple oral doses in healthy volunteers", Journal of Clinical Pharmacology, 6, pp.291~230 (2006)
- McCrea JB, "Effects of the neurokinin1 receptor antagonist aprepitant on the pharmacokinetics of dexamethasone and methylprednisolone", Clin Pharmacol Ther, 74, pp.17~24 (2003)
- Massaro AM, "Aprepitant, a novel antiemetic for chemotherapy -induced nausea and vomiting", Ann Pharmacother, 39, pp.77~85 (2005)
- Oechsle K, "Aprepitant as salvage therapy in patients with chemotherapy -induced nausea and emesis refractory to prophylaxis with 5- HT3 antagonists and dexamethasone", Onkologie, 29, pp.557~561 (2006)
- Gan TJ, "A randomized, double-blind comparison of the NK1 antagonist, aprepitant, versus ondansetron for the prevention of postoperative nausea and vomiting", Anesth Analg, 104, pp.1082~1089 (2007)
- Jenns K, "Importance of nausea", Cancer Nurs, 17(6), pp.488~493 (1994)
- Van Belle S, "Prevention of cisplatin-induced acute and delayed emesis by the selective neurokinin-1 antagonists, L-758,298 and MK-869", Cancer, 94, pp.3032~3041 (2002)
- Warr DG, "Chemotherapy-and cancer-related nausea and vomiting", Current Oncology, 15(1), pp.S4~S9 (2008)